137 related articles for article (PubMed ID: 33798535)
1. Melanoma Differentiation Trajectories Determine Sensitivity toward Pre-Existing CD8
Harbers FN; Thier B; Stupia S; Zhu S; Schwamborn M; Peller V; Chauvistré H; Crivello P; Fleischhauer K; Roesch A; Sucker A; Schadendorf D; Chen Y; Paschen A; Zhao F
J Invest Dermatol; 2021 Oct; 141(10):2480-2489. PubMed ID: 33798535
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
4. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
5. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS
Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
[TBL] [Abstract][Full Text] [Related]
6. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
7. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA
Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
[No Abstract] [Full Text] [Related]
9. BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation.
Hoyer S; Eberlein V; Schuler G; Berking C; Heinzerling L; Schaft N; Dörrie J
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769379
[TBL] [Abstract][Full Text] [Related]
10. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma.
Kim MH; Kim CG; Kim SK; Shin SJ; Choe EA; Park SH; Shin EC; Kim J
Cancer Immunol Res; 2018 Mar; 6(3):255-266. PubMed ID: 29382670
[TBL] [Abstract][Full Text] [Related]
11. Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.
Hao X; Falo Iii LD; Chen G; Zhang J; Carey CD; Storkus WJ; Falo LD; You Z
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408093
[TBL] [Abstract][Full Text] [Related]
12. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
13. BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes.
Peiffer L; Farahpour F; Sriram A; Spassova I; Hoffmann D; Kubat L; Stoitzner P; Gambichler T; Sucker A; Ugurel S; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2021 Jun; 70(6):1635-1647. PubMed ID: 33275172
[TBL] [Abstract][Full Text] [Related]
14. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity.
Melms JC; Vallabhaneni S; Mills CE; Yapp C; Chen JY; Morelli E; Waszyk P; Kumar S; Deming D; Moret N; Rodriguez S; Subramanian K; Rogava M; Cartwright ANR; Luoma A; Mei S; Brinker TJ; Miller DM; Spektor A; Schadendorf D; Riggi N; Wucherpfennig KW; Sorger PK; Izar B
Cancer Res; 2020 Feb; 80(4):798-810. PubMed ID: 31882401
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor is a determinant of melanoma targeted drug resistance.
Samarkina A; Youssef MK; Ostano P; Ghosh S; Ma M; Tassone B; Proust T; Chiorino G; Levesque MP; Goruppi S; Dotto GP
Nat Commun; 2023 Oct; 14(1):6498. PubMed ID: 37838724
[TBL] [Abstract][Full Text] [Related]
17. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
18. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma.
Cybulska-Stopa B; Rogala P; Czarnecka AM; Galus Ł; Dziura R; Rajczykowski M; Kubiatowski T; Wiśniewska M; Gęga-Czarnota A; Teterycz P; Ziobro M; Suwiński R; Mackiewicz J; Rutkowski P
Melanoma Res; 2020 Oct; 30(5):465-471. PubMed ID: 32221131
[TBL] [Abstract][Full Text] [Related]
19. PD-1
Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Szomolay B; Ott S; Dolton G; Lyngaa R; Hadrup SR; Sewell AK; Svane IM
Clin Cancer Res; 2017 Oct; 23(19):5779-5788. PubMed ID: 28679768
[No Abstract] [Full Text] [Related]
20. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.
Wilmott JS; Long GV; Howle JR; Haydu LE; Sharma RN; Thompson JF; Kefford RF; Hersey P; Scolyer RA
Clin Cancer Res; 2012 Mar; 18(5):1386-94. PubMed ID: 22156613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
